Diabetic nephropathy

Diabetic nephropathy is a progressive kidney disease associated with diabetes mellitus – type 1 and type 2 – affecting kidney glomeruli, arterioles, tubules and the interstitium. Clinical features include macroalbuminuria and a reduction in glomerular filtration rate that may lead to end-stage renal disease, requiring dialysis or kidney transplantation.

Latest Research and Reviews

News and Comment

  • News & Views |

    Clinical trials of sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists have shown beneficial effects of these agents on kidney outcomes in patients with type 2 diabetes mellitus. Two new cohort studies now demonstrate that these findings are generalizable to the broad range of patients seen in clinical practice.

    • Annemarie B. van der Aart-van der Beek
    •  & Hiddo J. L. Heerspink
  • Comments & Opinion |

    After nearly two decades, a new therapeutic agent, canagliflozin, received regulatory approval to prevent loss of kidney function, end-stage kidney disease, hospitalization for heart failure and cardiovascular death in patients with diabetic kidney disease. Nonetheless, the residual risk of kidney disease progression and complications remains high, underlining the importance of ongoing therapeutic development.

    • Katherine R. Tuttle
  • News & Views |

    A new genome-wide association study of patients with type 1 diabetes mellitus reveals novel loci that are associated with the development of diabetic kidney disease. The most significant of these loci encodes the α3 chain of type IV collagen, which is an important component of the glomerular basement membrane.

    • Jeffrey H. Miner
  • News & Views |

    Inhibitors of sodium–glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase 4 (DPP4) are widely used in patients with type 2 diabetes to improve glycaemic control and reduce cardiovascular risks. Two recent clinical trials, CREDENCE and DELIGHT, demonstrate that these drugs can also slow down the progression of kidney disease in these patients.

    • Christoph Wanner
    •  & Susanne Brenner